Share This Page
Drug Price Trends for VOQUEZNA TRIPLE PAK
✉ Email this page to a colleague
Average Pharmacy Cost for VOQUEZNA TRIPLE PAK
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VOQUEZNA TRIPLE PAK | 81520-0255-01 | 7.27053 | EACH | 2025-01-01 |
| VOQUEZNA TRIPLE PAK | 81520-0255-14 | 7.27053 | EACH | 2025-01-01 |
| VOQUEZNA TRIPLE PAK | 81520-0255-14 | 6.92432 | EACH | 2024-12-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for VOQUEZNA TRIPLE PAK
Introduction to VOQUEZNA TRIPLE PAK
VOQUEZNA TRIPLE PAK, developed by Phathom Pharmaceuticals, is a significant advancement in the treatment of Helicobacter pylori (H. pylori) infections and other acid-related disorders. The drug combines amoxicillin, clarithromycin, and vonoprazan, offering a comprehensive treatment regimen.
Market Performance and Adoption
The commercial launch of VOQUEZNA TRIPLE PAK has shown promising results. As of the third quarter of 2024, the total filled prescriptions for VOQUEZNA products, including VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, have significantly increased. Over 143,000 prescriptions were filled through October 25, 2024, representing a 138% increase from the previous quarter's 60,000 prescriptions[1].
This rapid adoption is attributed to the drug's effectiveness and the recent label expansion to include Non-Erosive GERD, which has enhanced its market appeal among healthcare providers and patients.
Pricing and Cost Considerations
The cost of VOQUEZNA TRIPLE PAK is substantial, reflecting its brand-name status and the lack of a generic alternative. For cash-paying customers, the cost for a supply of 112 kits (each kit containing 14 days of treatment) is approximately $864.54, or $7.72 per unit[2].
However, patients can benefit from discount programs such as the Drugs.com Discount Card, which can save up to 80% off the cost of prescription medicines at major pharmacies across the U.S.[2].
Market Forecast and Projections
The market for VOQUEZNA TRIPLE PAK is expected to grow significantly over the coming years. Here are some key projections:
Sales Growth
The sales data for VOQUEZNA TRIPLE PAK indicates a strong growth trajectory. In the third quarter of 2024, net revenues from VOQUEZNA products were $16.4 million, up from $7.3 million in the second quarter of 2024. This growth is expected to continue as the drug gains more market acceptance and expands its treatment indications[1][4].
Market Size
The U.S. market for VOQUEZNA TRIPLE and DUAL PAKs is forecasted to expand significantly from 2023 to 2032. The detailed analysis provided in market reports suggests that the market size will increase, driven by extensive research, incremental healthcare spending, and the drug's efficacy in treating H. pylori infections[5].
Competitive Landscape
While VOQUEZNA TRIPLE PAK currently holds a strong position in the market, it is expected to face competition from emerging therapies. The launch of late-stage therapies in the near future could impact its market dominance. However, Phathom Pharmaceuticals' commitment to building VOQUEZNA into a potential blockbuster and its ongoing efforts to enhance the treatment landscape for acid-related disorders are likely to maintain its competitive edge[5].
Global Medicine Spending Trends
The global medicine market, including the segment for H. pylori treatments, is expected to grow at a CAGR of 3-6% through 2025, reaching a total market size of about $1.6 trillion. This growth is driven by the adoption of new treatments, offset by patent lifecycles and competition from generics and biosimilars[3].
Impact on VOQUEZNA TRIPLE PAK
The global trends in medicine spending will positively impact VOQUEZNA TRIPLE PAK. As healthcare access increases, especially in pharmerging countries like China, the demand for effective treatments for H. pylori infections is likely to rise. This will create additional market opportunities for VOQUEZNA TRIPLE PAK, contributing to its projected growth[3].
Regulatory and Developmental Milestones
The regulatory and developmental activities surrounding VOQUEZNA TRIPLE PAK are crucial for its market success. The recent label expansion and ongoing research to improve the drug's efficacy and safety profile are key milestones. These efforts ensure that VOQUEZNA TRIPLE PAK remains a leading treatment option for H. pylori infections and other related conditions[5].
Challenges and Opportunities
Challenges
Despite its strong market performance, VOQUEZNA TRIPLE PAK faces several challenges:
- Competition from Emerging Therapies: The launch of new therapies could pose a significant challenge to its market dominance.
- Cost and Accessibility: The high cost of the drug may limit its accessibility for some patients, although discount programs can mitigate this issue.
Opportunities
- Expanding Treatment Indications: The recent inclusion of Non-Erosive GERD in its label and potential future expansions can increase its market reach.
- Global Healthcare Trends: The growing demand for effective treatments in both developed and emerging markets presents significant opportunities for growth.
Key Takeaways
- Strong Market Adoption: VOQUEZNA TRIPLE PAK has seen rapid adoption with over 143,000 prescriptions filled as of October 25, 2024.
- Pricing: The drug is priced at around $864.54 for a supply of 112 kits, with potential savings through discount programs.
- Market Forecast: The market for VOQUEZNA TRIPLE PAK is expected to grow significantly from 2023 to 2032, driven by its efficacy and expanding treatment indications.
- Global Trends: The global medicine market's growth trends will positively impact VOQUEZNA TRIPLE PAK, especially in pharmerging countries.
- Regulatory and Developmental Activities: Ongoing research and regulatory milestones are crucial for maintaining its competitive edge.
FAQs
What is VOQUEZNA TRIPLE PAK used for?
VOQUEZNA TRIPLE PAK is used for the treatment of Helicobacter pylori (H. pylori) infections and other acid-related disorders, including Non-Erosive GERD.
How much does VOQUEZNA TRIPLE PAK cost?
The cost for a supply of 112 kits of VOQUEZNA TRIPLE PAK is approximately $864.54, or $7.72 per unit, for cash-paying customers.
Is there a generic version of VOQUEZNA TRIPLE PAK available?
No, a generic version of VOQUEZNA TRIPLE PAK is not yet available.
What are the key factors driving the growth of VOQUEZNA TRIPLE PAK in the market?
The growth of VOQUEZNA TRIPLE PAK is driven by its strong adoption rates, expanding treatment indications, and the overall increase in healthcare spending and access.
How does VOQUEZNA TRIPLE PAK compare to other treatments for H. pylori infections?
VOQUEZNA TRIPLE PAK offers a comprehensive treatment regimen combining amoxicillin, clarithromycin, and vonoprazan, making it a highly effective option. However, it may face competition from emerging therapies in the future.
Sources
- Phathom Pharmaceuticals Reports Third Quarter 2024 Financial Results. Phathom Pharmaceuticals.
- Voquezna Triple Pak Prices, Coupons, Copay Cards & Patient Assistance. Drugs.com.
- Global Medicine Spending and Usage Trends: Outlook to 2025. IQVIA.
- Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results. Phathom Pharmaceuticals.
- US VOQUEZNA TRIPLE and DUAL PAKs Drug Insight and Market Forecast - 2032. ResearchAndMarkets.
More… ↓
